0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-484.80%PremiumSep 20, 2024Expiry Date4.15Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Equillium Stock Discussion
is this stock still even alive
$Equillium (EQ.US)$
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads...
Equillium Announces Positive Topline Data From Phase 2 Study of EQ101 in Alopecia Areata
Equillium Inc: EQ101 Was Well Tolerated in Subjects With Alopecia Areata With No Serious Adverse Events Reported
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
No comment yet